Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-Time-in-Human Study of GSK5471713 in Adults With Metastatic Castration-Resistant Prostate Cancer
2025-523874-17-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of GSK5471713 in castration-resistant prostate cancer (CRPC), sponsored by GSK. Primary endpoints: Dose-limiting toxicities at each dose level, Adverse events, serious adverse events, and adverse events leading to dose modifications (incidence) and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
GSK5471713
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2025-523874-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523874-17-00.